REG - Syncona Limited - Syncona to acquire Freeline Therapeutics Holdings

SynconaAnnouncement

22/11/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231122:nRSV3378Ua&default-theme=true

RNS Number : 3378U  Syncona Limited  22 November 2023

22 November 2023

Syncona Limited

Syncona to acquire Freeline Therapeutics Holdings plc

·      A newly established portfolio company of Syncona has entered into
an agreement with Freeline to acquire all of the shares of Freeline that
Syncona does not currently own in an all-cash transaction that values the
entire issued share capital of Freeline at c.$28.3 million

·      Freeline represents a differentiated opportunity to invest in
line with capital allocation focus on clinical assets with the potential to
reach late-stage development in the near term

·      In conjunction with the agreement, Syncona will provide up to $15
million of financing to enable Freeline to meet its near-term cash
requirements, to continue to advance FLT201 and to continue to execute on plan

Syncona Ltd ("Syncona" or the "Company"), a leading life science investor
focused on creating, building and scaling global leaders in life science,
today announces that its newly established portfolio company has entered into
an agreement with Freeline Therapeutics Holdings plc ("Freeline") to acquire
all of the shares of Freeline that Syncona does not currently own in an
all-cash transaction. Syncona currently owns 49.7% of Freeline. 1 

Under the agreement, a newly established Syncona portfolio company will
acquire Freeline for $6.50 in cash for each Freeline American Depositary Share
(ADS). This price values the entire issued share capital of Freeline at
approximately $28.3 million and represents a 50% premium to Freeline's closing
price prior to the announcement on October 18 of Syncona's initial proposal to
take Freeline private. The acquisition is subject to approval or acceptance by
the required number of Freeline's minority shareholders and is expected to
close in the first quarter of 2024.

Syncona is highly supportive of Freeline's lead programme, FLT201, a potential
first- and best-in-class gene therapy for Gaucher disease, a debilitating
condition where there is a clear need for better treatment options. Syncona
believes there is considerable potential for a one-time gene therapy that can
deliver durable expression of the GCase enzyme which is deficient in Gaucher
disease patients.

Chris Hollowood, CEO of Syncona Investment Management Limited, said: "We
continue to be excited by the data published by Freeline in its FLT201
programme and are pleased with how the company is executing. Our capital
allocation is resolutely focused on opportunities with strong prospects of
driving an asset to late-stage development, where we believe significant value
can be accessed. The challenging market conditions impacting the biotech
sector have presented a differentiated opportunity to deploy capital in line
with that approach. The flexibility of the Syncona platform, enabled by our
capital pool, allows us to optimise how we do this and, in this instance,
taking the company private allows us the best route to potential risk-adjusted
returns."

In conjunction with the agreement, Syncona is committing to provide Freeline
with up to $15 million of financing 2  (#_ftn2) . This will enable Freeline to
advance its lead FLT201 therapy in Gaucher disease, as well as continuing to
advance its GBA1-linked Parkinson's disease research programme.

 ENDS 

Syncona Investor and Media Contacts:

Syncona Ltd

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

Terms of the Going-Private transaction

It is intended that the acquisition will be implemented by means of a scheme
of arrangement under Part 26 of the UK Companies Act 2006, whereby the entire
issued and to be issued share capital of Freeline that Syncona does not
already own will be acquired by a newly established Syncona portfolio company.
The acquisition is conditional on, among other things: (i) the approval by not
less than 75 percent in value of the Freeline shareholders present, entitled
to vote and voting, either in person or by proxy, at each of the court meeting
and the general meeting to be convened to approve the Scheme; and (ii) the
sanction of the Scheme by the U.K. Court. Syncona will not be entitled to vote
at the Court Meeting. The acquisition does not require the approval of
Syncona's shareholders.

 

If completed, the acquisition will result in the company becoming a wholly
owned Syncona portfolio company, and its ADSs will no longer be listed on
Nasdaq.

 

Freeline will furnish to the U.S. Securities and Exchange Commission (the
"SEC") a current report on Form 6-K regarding the acquisition, which will
include as an exhibit thereto the Implementation Agreement. All parties
desiring details regarding the acquisition are urged to review these
documents, which will be available at the SEC's website (http://www.sec.gov).

 

Further details of the acquisition will be contained in the Scheme Document to
be made available to Freeline shareholders along with notices of the Court
Meeting and General Meeting and the Forms of Proxy.

 

In connection with the acquisition, Syncona and Freeline will prepare and mail
a Schedule 13E-3 Transaction Statement (the "Schedule 13E-3"). The Schedule
13E-3 will be filed with the SEC. INVESTORS AND SHAREHOLDERS IN FREELINE ARE
URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE SCHEDULE 13E-3 AND OTHER
MATERIALS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT FREELINE, THE ACQUISITION, AND RELATED MATTERS. In
addition to receiving the Schedule 13E-3 by mail, shareholders also will be
able to obtain these documents, as well as other filings containing
information about Freeline, the acquisition, and related matters, without
charge from the SEC's website (http://www.sec.gov (http://www.sec.gov) ).

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting as US legal
counsel to Syncona; and Simmons & Simmons LLP is acting as UK legal
counsel to Syncona. Leerink Partners is acting as an exclusive financial
advisor to Board of Freeline's Special Committee, and Skadden, Arps, Slate,
Meagher & Flom LLP is acting as legal counsel to the Board of Freeline's
Special Committee.

 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need. Our strategy is to create, build and
scale companies around exceptional science to create a diversified portfolio
of 20-25 globally leading healthcare businesses, across development stage and
therapeutic areas, for the benefit of all our stakeholders. We focus on
developing treatments for patients by working in close partnership with
world-class academic founders and management teams. Our balance sheet
underpins our strategy enabling us to take a long-term view as we look to
improve the lives of patients with no or poor treatment options, build
sustainable life science companies and deliver strong risk-adjusted returns to
shareholders.

 

Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of investments
of Syncona Limited, the proposed transactions between Syncona Limited and
Freeline, future opportunities for the combined company and other statements
about future expectations, beliefs, goals, plans or prospects. These
statements and forecasts involve risk and uncertainty because they relate to
events and depend upon circumstances that may or may not occur in the future.
There are a number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these forward-looking
statements. In particular, many companies in the Syncona Limited portfolio
are conducting scientific research and clinical trials where the outcome is
inherently uncertain and there is significant risk of negative results or
adverse events arising and many such companies have yet to commercialise a
product and their ability to do so may be affected by operational, commercial
and other risks.

 

Syncona Limited seeks to achieve returns over the long term. Investors should
seek to ensure they understand the risks and opportunities of an investment in
Syncona Limited, including the information in our published documentation,
before investing.

 

 

 1  (#_ftnref1) Fully diluted ownership position; 58% on issued share capital
basis

 2  (#_ftnref2) Financing is in the form of secured convertible debt

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQFLFSILFLFFIV